
Last updated: 2026-09-16 17:54:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Filana Therapeutics, Inc. (FLNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.68, with a market capitalisation of $34.72M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.67 to $2.27. This page covers its latest market performance, valuation, price trends and company information.
$34.72M | |
$0.69 | |
$2.27 | |
$0.67 | |
$0.70 | |
216.59K | |
321.81K | |
-- | |
$2.27 | |
$0.67 | |
-- | |
-- |
Filana Therapeutics, Inc. (FLNA) is currently trading at $0.68 as of 2026-09-16 17:37:45, down 2.23% ($0.02) from the previous close of $0.70
During today's regular trading session, FLNA has traded between $0.67 and $2.27, with a trading volume of 216.59K shares. The current price is near the lower end of today's range.
Over the past seven days, Filana Therapeutics, Inc. (FLNA) moved from $0.82 to $0.68, representing a decline of 16.96% ($0.14).
The stock traded between $0.67 and $0.85 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 360.35 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.6%
FLNA is currently trading at $0.68, placing it 0.6% of the way from its 52-week low of $0.67 to its 52-week high of $2.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Filana Therapeutics, Inc. (FLNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.